Aurobindo Pharma receives USFDA approval for Metformin Hydrochloride ER tablets

23 Jul 2012 Evaluate

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Metformin Hydrochloride Extended-Release (ER) Tablets USP 500mg and 750mg (ANDA 079118). The product is ready for launch.

Metformin Hydrochloride ER Tablets USP 500mg and 750mg is the generic equivalent of Bristol Myers Squibb Company (BMS)'s Glucophage XR Extended-release Tablets 500mg and 750mg respectively. Metformin Hydrochloride ER Tablets are oral anti-hyperglycemic drugs indicated as an adjunct to diet and exercise to improve glycemic control in patients with type-2 diabetes. The annual sale of the product is approximately $230 million.

The product has been approved out of Unit III formulations facility in Hyderabad, India. The company now has a total of 153 ANDA approvals (127 Final approvals including 1 from Aurolife Pharma LLC and 26 tentative approvals) from USFDA.

Aurobindo Pharma has a product presence in key therapeutic segments like SSPs, cephalosporins, antivirals, CNS, cardio-vascular, gastroenterology, etc. The company is the market leader in semi-synthetic penicillin drugs.

Aurobindo Pharma Share Price

1203.90 0.00 (0.00%)
18-May-2024 12:50 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1532.85
Dr. Reddys Lab 5812.50
Cipla 1403.90
Zydus Lifesciences 1104.45
Lupin 1661.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.